Hematopoietic growth factors in myelodysplastic syndromes

Seminars in Oncology

Volumn 38, Issue 5, 2011, Pages 635-647

  Steensma, David P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIANEMIC AGENT; ANTIFIBRINOLYTIC AGENT; AZACITIDINE; COLECALCIFEROL; COLONY STIMULATING FACTOR 1; ELTROMBOPAG; HEMOPOIETIC GROWTH FACTOR; HEMOSTATIC AGENT; INTERLEUKIN 3; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PMA 112509; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT THROMBOPOIETIN; RETINOIC ACID; ROMIPLOSTIM; THALIDOMIDE; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; BONE PAIN; CLINICAL TRIAL (TOPIC); CYTOPENIA; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; FLU LIKE SYNDROME; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEART ATRIUM ARRHYTHMIA; HEMATOPOIETIC CELL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LUNG INFILTRATE; MONOTHERAPY; MUCOSAL BLEEDING; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHILIC DERMATOSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

BENZOIC ACIDS; COLONY-STIMULATING FACTORS; DRUG TOXICITY; EPOETIN ALFA; ERYTHROPOIETIN; FILGRASTIM; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEMATINICS; HUMANS; HYDRAZINES; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; PYRAZOLES; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; THROMBOPOIETIN;

EID: 80053204645     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.014     Document Type: Article

References (104)

1. D.P. Steensma, and J.M. Bennett The myelodysplastic syndromes: diagnosis and treatment Mayo Clin Proc 81 2006 104 130 (Pubitemid 43054324)
2. S. Vadhan-Raj, M. Keating, and A. LeMaistre Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes N Engl J Med 317 1987 1545 1552 (Pubitemid 18014381)
3. C. Stebler, A. Tichelli, H. Dazzi, A. Gratwohl, C. Nissen, and B. Speck High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study Exp Hematol 18 1990 1204 1208
4. M. Bessho, I. Jinnai, A. Matsuda, M. Saito, and K. Hirashima Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia Int J Cell Cloning 8 1990 445 458 (Pubitemid 20359754)
5. H.C. Schouten, E. Vellenga, D.J. van Rhenen, J.T. de Wolf, P.J. Coppens, and G.H. Blijham Recombinant human erythropoietin in patients with myelodysplastic syndromes Leukemia 5 1991 432 436
6. D. Hoelzer, A. Ganser, J. Greher, B. Volkers, and F. Walther Phase I/II study with GM-CSF in patients with myelodysplastic syndromes Behring Inst Mitt 1988 134 138 (Pubitemid 19239250)
7. W. Jelkmann Erythropoietin after a century of research: younger than ever Eur J Haematol 78 2007 183 205
8. T. Miyake, C.K. Kung, and E. Goldwasser Purification of human erythropoietin J Biol Chem 252 1977 5558 5564 (Pubitemid 8167007)
9. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, and J.W. Adamson Correction of the anemia of end-stage renal disease with recombinant human erythropoietin Results of a combined phase I and II clinical trial N Engl J Med 316 1987 73 78 (Pubitemid 17052741)
10. E. Hellstrom, G. Birgegard, D. Lockner, C. Helmers, A. Ost, and L. Wide Treatment of myelodysplastic syndromes with recombinant human erythropoietin Eur J Haematol 47 1991 355 360
11. R.S. Stein, R.I. Abels, and S.B. Krantz Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes Blood 78 1991 1658 1663
12. P.L. Storring, R.J. Tiplady, and R.E. Gaines Das Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties Br J Haematol 100 1998 79 89 (Pubitemid 28051844)
13. R.M. Stone, S.H. Bernstein, and G. Demetri Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes Leuk Res 18 1994 769 776 (Pubitemid 24302104)
14. J.C. Egrie, and J.K. Browne Development and characterization of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant 16 Suppl 3 2001 3 13 (Pubitemid 32591159)
15. P. Musto, F. Lanza, and E. Balleari Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes Br J Haematol 128 2005 204 209
16. J.F. Patton, T. Sullivan, Y. Mun, T. Reeves, G. Rossi, and J.F. Wallace A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome J Support Oncol 3 2005 419 426 (Pubitemid 43230613)
17. R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann Oncol 16 2005 1921 1927 (Pubitemid 41724281)
18. D.P. Steensma, K.V. Heptinstall, and V.M. Johnson Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey Leuk Res 32 2008 691 698 (Pubitemid 351323939)
19. M.A. Sekeres, W.M. Schoonen, and H. Kantarjian Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys J Natl Cancer Inst 100 2008 1542 1551
20. M.A. Sekeres, J.M. Maciejewski, and A.F. List Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey Oncologist 16 2011 904 911
21. D. Bowen, D. Culligan, and S. Jowitt Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2003 187 200 (Pubitemid 36194166)
22. P.L. Greenberg NCCN Panel National Comprehensive Cancer Network (NCCN) clinical practic guidelines in oncology: myelodysplastic syndromes (v2. 2010) [cited 2010 June 13] http://www.nccn.org/professionals/physician-gls/PDF/mds.pdf 2010
23. P. Valent, H.P. Horny, and J.M. Bennett Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference Leuk Res 31 2007 727 736 (Pubitemid 46855901)
24. J.D. Rizzo, M.R. Somerfield, and K.L. Hagerty Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update Blood 111 2008 25 41
25. E.P. Alessandrino, S. Amadori, and G. Barosi Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes A statement from the Italian Society of Hematology Haematologica 87 2002 1286 1306 (Pubitemid 36005304)
26. M. Jadersten, S.M. Montgomery, I. Dybedal, A. Porwit-MacDonald, and E. Hellstrom-Lindberg Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF Blood 106 2005 803 811 (Pubitemid 41076418)
27. S. Park, S. Grabar, and C. Kelaidi Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood 111 2008 574 582
28. N. Casadevall, P. Durieux, and S. Dubois Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 2004 321 327 (Pubitemid 38900010)
29. P.L. Greenberg, Z. Sun, and K.B. Miller Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) Blood 114 2009 2393 2400
30. V. Moyo, P. Lefebvre, M.S. Duh, B. Yektashenas, and S. Mundle Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis Ann Hematol 87 2008 527 536
31. B.D. Cheson, J.M. Bennett, and H. Kantarjian Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
32. S.D. Ross, I.E. Allen, C.A. Probst, B. Sercus, S.M. Crean, and G. Ranganathan Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis Oncologist 12 2007 1264 1273 (Pubitemid 350106357)
33. L.H. Hoefsloot, M.P. van Amelsvoort, and L.C. Broeders Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome Blood 89 1997 1690 1700 (Pubitemid 27097463)
34. G. Sterner, and K.G. Prutz Conversion from epoetin beta to darbepoetin: what is the equivalent dose? Nephrol Dial Transplant 23 2008 4084 4085
35. L. Mannone, C. Gardin, and M.C. Quarre High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study Br J Haematol 133 2006 513 519
36. S. Mundle, P. Lefebvre, F. Vekeman, M.S. Duh, R. Rastogi, and V. Moyo An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach Cancer 115 2009 706 715
37. E. Balleari, E. Rossi, and M. Clavio Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study Ann Hematol 85 2006 174 180 (Pubitemid 43174272)
38. A. Tefferi, M.A. Elliott, and D.P. Steensma Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome Leuk Res 25 2001 183 185 (Pubitemid 32141123)
39. R. Itzykson, S. Ayari, and D. Vassilief Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases Leukemia 23 2009 673 678
40. R. Stasi, M. Brunetti, E. Terzoli, and S. Amadori Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes Blood 99 2002 1578 1584 (Pubitemid 34533029)
41. A. Ganser, A. Maurer, and C. Contzen Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol Ann Hematol 72 1996 237 244
42. D. Ferrero, A. Darbesio, and V. Giai Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes Br J Haematol 144 2009 342 349
43. E.C. Besa, S. Kunselman, and P.C. Nowell A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias The Central Pennsylvania Oncology Group Leuk Res 22 1998 741 749 (Pubitemid 28327481)
44. P. Musto, A. Falcone, G. Sanpaolo, and C. Bodenizza Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes Leuk Res 30 2006 385 388 (Pubitemid 43254959)
45. M. Steurer, I. Sudmeier, R. Stauder, and G. Gastl Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha Br J Haematol 121 2003 101 103 (Pubitemid 36461274)
46. E. Hellstrom-Lindberg Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies Br J Haematol 89 1995 67 71
47. W.K. Cheung, B.L. Goon, M.C. Guilfoyle, and M.C. Wacholtz Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects Clin Pharmacol Ther 64 1998 412 423 (Pubitemid 28473767)
48. E. Hellstrom-Lindberg, R. Negrin, and R. Stein Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model Br J Haematol 99 1997 344 351 (Pubitemid 27497565)
49. E. Hellstrom-Lindberg, N. Gulbrandsen, and G. Lindberg A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 2003 1037 1046 (Pubitemid 36411563)
50. R. Stasi, M. Brunetti, and S. Bussa Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome Clin Lab Haematol 19 1997 197 201 (Pubitemid 27431473)
51. P. Musto, R. Matera, and M.M. Minervini Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin Haematologica 79 1994 265 268 (Pubitemid 24255774)
52. C. Kelaidi, S. Park, and S. Brechignac Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide Leuk Res 32 2008 1049 1053
53. A.A. Giagounidis, U. Germing, J.S. Wainscoat, J. Boultwood, and C. Aul The 5q- syndrome Hematology 9 2004 271 277
54. T.M. Westers, C. Alhan, and M.E. Chamuleau Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment Blood 115 2010 1779 1784
55. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes Br J Haematol 103 1998 1070 1074
56. D. Bowen, A. Hyslop, and N. Keenan Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia Haematologica 91 2006 709 710 (Pubitemid 43799477)
57. M. Jadersten, L. Malcovati, and I. Dybedal Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome J Clin Oncol 26 2008 3607 3613
58. K. Nachtkamp, A. Kundgen, and C. Strupp Impact on survival of different treatments for myelodysplastic syndromes (MDS) Leuk Res 33 2009 1024 1028
59. A.R. Golshayan, T. Jin, and J. Maciejewski Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes Br J Haematol 137 2007 125 132 (Pubitemid 46474717)
60. E.H. Rose, R.I. Abels, R.A. Nelson, D.M. McCullough, and L. Lessin The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS) Br J Haematol 89 1995 831 837
61. J. Bohlius, K. Schmidlin, and C. Brillant Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 2009 1532 1542
62. D.P. Steensma Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe? Am J Hematol 84 2009 3 5
63. P.L. Greenberg, Z. Sun, and K.B. Miller Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996) Blood 114 2009 2393 2400
64. B.D. Cheson, P.L. Greenberg, and J.M. Bennett Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2006 419 425 (Pubitemid 44061337)
65. S. Elliott, L. Busse, and I. McCaffery Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells J Immunol Methods 352 2010 126 139
66. S. Swift, A.R. Ellison, and P. Kassner Absence of functional EpoR expression in human tumor cell lines Blood 115 2010 4254 4263
67. D. Metcalf The granulocyte-macrophage colony-stimulating factors Science 229 1985 16 22
68. D. Metcalf Hematopoietic cytokines Blood 111 2008 485 491
69. N. Berliner Lessons from congenital neutropenia: 50 years of progress in understanding myelopoiesis Blood 111 2008 5427 5432
70. N.M. Gough, J. Gough, and D. Metcalf Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor Nature 309 1984 763 767 (Pubitemid 14119427)
71. C.E. Brandao-Mello, A.R. Oliveira, N.J. Valverde, R. Farina, and J.M. Cordeiro Clinical and hematological aspects of 137Cs: the Goiania radiation accident Health Phys 60 1991 31 39
72. L.M. Souza, T.C. Boone, and J. Gabrilove Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells Science 232 1986 61 65 (Pubitemid 16037976)
73. S. Nagata, M. Tsuchiya, and S. Asano Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor Nature 319 1986 415 418 (Pubitemid 16163903)
74. J.L. Gabrilove, A. Jakubowski, and K. Fain Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium J Clin Invest 82 1988 1454 1461
75. P. Greenberg, R. Negrin, A. Nagler, M. Vincent, and T. Donlon Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor Int J Cell Cloning 8 Suppl 1 1990 293 300
76. R.S. Negrin, D.H. Haeuber, and A. Nagler Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor Blood 76 1990 36 43 (Pubitemid 20220788)
77. A. Jakob, F.W. Hirsch, and M. Engelhardt Successful treatment of a patient with myelodysplastic syndrome (RAEB) with darbepoetin-alfa in combination with pegfilgrastim Ann Hematol 84 2005 694 695 (Pubitemid 41554249)
78. R. Willemze, N. van der Lely, and H. Zwierzina A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia EORTC Leukemia Cooperative Group Ann Hematol 64 1992 173 180
79. C. Kelleher, J. Miyauchi, G. Wong, S. Clark, M.D. Minden, and E.A. McCulloch Synergism between recombinant growth factors, GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukemia Blood 69 1987 1498 1503 (Pubitemid 17085314)
80. T. Hoang, N. Nara, G. Wong, S. Clark, M.D. Minden, and E.A. McCulloch Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia Blood 68 1986 313 316 (Pubitemid 16033651)
81. P. Greenberg, K. Taylor, and R.A. Larson Phase III randomized multicenter trial of recombinant human G-CSF in MDS [abstract] Blood (ASH Annual Meeting Extracts) 82 Suppl 1 1993 196a
82. M.W. Schuster, J.A. Thompson, and R.A. Larson Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients (pts) with myelodysplastic syndrome (MDS) J Cancer Res Clin Oncol 116 1990 1079a
83. S. Bidyasar, M. Montoya, K. Suleman, and A.B. Markowitz Sweet syndrome associated with granulocyte colony-stimulating factor J Clin Oncol 26 2008 4355 4356
84. M. Arshad, K. Seiter, and J. Bilaniuk Side effects related to cancer treatment: CASE 2 Splenic rupture following pegfilgrastim J Clin Oncol 23 2005 8533 8534
85. K. Kaushansky Thrombopoietin N Engl J Med 339 1998 746 754 (Pubitemid 28417359)
86. D.J. Kuter, D.L. Beeler, and R.D. Rosenberg The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production Proc Natl Acad Sci U S A 91 1994 11104 11108 (Pubitemid 24349634)
87. K. Kaushansky Lineage-specific hematopoietic growth factors N Engl J Med 354 2006 2034 2045
88. J. Li, C. Yang, and Y. Xia Thrombocytopenia caused by the development of antibodies to thrombopoietin Blood 98 2001 3241 3248
89. D.J. Kuter, and C.G. Begley Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood 100 2002 3457 3469 (Pubitemid 35303910)
90. D.J. Kuter New thrombopoietic growth factors Blood 109 2007 4607 4616 (Pubitemid 46827750)
91. H. Kantarjian, P. Fenaux, and M.A. Sekeres Phase 1/2 Study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract] ASH Annual Meeting Abstracts 110 2007 250
92. S. Wroblewski, W. Shi, P. Mudd Jr, and M. Aivado Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: a phase I/II study [abstract TPS184] J Clin Oncol 28 Suppl 2010
93. H. Kantarjian, F. Giles, and A. List The incidence and impact of thrombocytopenia in myelodysplastic syndromes Cancer 109 2007 1705 1714 (Pubitemid 46668530)
94. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088 (Pubitemid 27132124)
95. M.E. Salacz, M.W. Lankiewicz, and D.E. Weissman Management of thrombocytopenia in bone marrow failure: a review J Palliat Med 10 2007 236 244 (Pubitemid 46238970)
96. R. Kurzrock, J. Cortes, D.A. Thomas, S. Jeha, S. Pilat, and M. Talpaz Pilot study of low-dose interleukin-11 in patients with bone marrow failure J Clin Oncol 19 2001 4165 4172 (Pubitemid 33049535)
97. H. Kantarjian, P. Fenaux, and M.A. Sekeres Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia J Clin Oncol 28 2010 437 444
98. P. Fenaux, H. Kantarjian, and R. Lyons An open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients (pts) with myelodysplastic syndromes (MDS) [abstract] ASH Annual Meeting Abstracts 114 2009 2765
99. J.L. Villeval, K. Cohen-Solal, and M. Tulliez High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice Blood 90 1997 4369 4383 (Pubitemid 27508443)
100. D.J. Kuter, G.J. Mufti, B.J. Bain, R.P. Hasserjian, W. Davis, and M. Rutstein Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim Blood 114 2009 3748 3756
101. S.S. Luo, K. Ogata, N. Yokose, T. Kato, and K. Dan Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes Stem Cells 18 2000 112 119 (Pubitemid 30176805)
102. H. Kantarjian, F. Giles, and P. Greenberg Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine [abstract] ASH Annual Meeting Abstracts 112 2008 224
103. P.L. Greenberg, G. Garcia-Manero, and M.R. Moore Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract] ASH Annual Meeting Abstracts 114 2009 1769
104. R.M. Lyons, R.A. Larson, and M.A. Kosmo Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving Lenalidomide [abstract] ASH Annual Meeting Abstracts 114 2009 1770